Michael S. Geltzeiler net worth and biography

Michael Geltzeiler Biography and Net Worth

Director of Hyperion DeFi

Michael Geltzeiler joined as an independent director and chair of our audit committee in November 2023. Mike comes to us with more than 35 years of senior financial leadership experience, including as former Chief Financial Officer of ADT Corporation, NYSE Euronext, Reader’s Digest Association, and ACNielsen. In addition to his role as CFO, Geltzeiler worked for ACNielsen Corporation as senior vice president & controller, and CFO for ACNielsen Europe, Middle East, and Africa. He also held a variety of positions, in the United States and abroad, for the Dun & Bradstreet Corporation, a provider of commercial information and insight on businesses. Michael previously served on the Boards of Cypress Creek Renewables and the Euronext Supervisory Board and is currently a board member for Madison Square Boys and Girls Club and the University of Delaware.

What is Michael S. Geltzeiler's net worth?: The estimated net worth of Michael S. Geltzeiler is at least $334.90 thousand as of December 17th, 2025. Mr. Geltzeiler owns 88,015 shares of Hyperion DeFi stock worth more than $334,897 as of September 23rd. This net worth evaluation does not reflect any other investments that Mr. Geltzeiler may own. Learn More about Michael S. Geltzeiler's net worth.
How do I contact Michael S. Geltzeiler?: The corporate mailing address for Mr. Geltzeiler and other Hyperion DeFi executives is 3090 Nowitzki Way, Suite 300, Dallas, TX, 75219. Hyperion DeFi can also be reached via phone at (833) 393-6684 and via email at [email protected]. Learn More on Michael S. Geltzeiler's contact information.
Has Michael S. Geltzeiler been buying or selling shares of Hyperion DeFi?: Michael S. Geltzeiler has not been actively trading shares of Hyperion DeFi during the last ninety days. Most recently, on Wednesday, December 17th, Michael S. Geltzeiler bought 30,000 shares of Hyperion DeFi stock. The stock was acquired at an average cost of $3.01 per share, with a total value of $90,300.00. Following the completion of the transaction, the director now directly owns 88,015 shares of the company's stock, valued at $264,925.15. Learn More on Michael S. Geltzeiler's trading history.
Who are Hyperion DeFi's active insiders?: Hyperion DeFi's insider roster includes Michael Geltzeiler (Director), Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Hyunsu Jung (Chief Executive Officer), David Knox (CFO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), Michael Rowe (COO), Ellen Strahlman (Director), and Happy Walters (Director). Learn More on Hyperion DeFi's active insiders.
Are insiders buying or selling shares of Hyperion DeFi?: In the last twelve months, Hyperion DeFi insiders bought shares 11 times. They purchased a total of 197,204 shares worth more than $641,026.94. The most recent insider tranaction occured on June, 2nd when insider Hyunsu Jung bought 1,000 shares worth more than $3,660.00. Insiders at Hyperion DeFi own 7.5% of the company. Learn More about insider trades at Hyperion DeFi.
Information on this page was last updated on 6/2/2026.

Michael S. Geltzeiler Insider Trading History at Hyperion DeFi

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/17/2025	Buy	30,000	$3.01	$90,300.00	88,015

Michael S. Geltzeiler Buying and Selling Activity at Hyperion DeFi

Hyperion DeFi Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Today's Range

Now: $3.85

$3.71

$3.89

50 Day Range

MA: $3.05

$2.34

$3.99

2 Week Range

Now: $3.85

$2.34

$11.89

Volume

309,089 shs

Average Volume

468,073 shs

Market Capitalization

$59.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.53